-+ 0.00%
-+ 0.00%
-+ 0.00%

Citibank: Raising the target price of Hewang Pharmaceuticals (00013) to HK$45.3 to maintain the “buy/high risk” rating and preferred stock status

Zhitongcaijing·11/20/2026 07:09:08
Listen to the news

The Zhitong Finance App learned that Citi released a research report saying that Hehuang Pharmaceutical (00013) sovleplenib was approved by the China National Drug Administration (NMPA), earlier than the first half of 2027 according to the company's guidelines. The bank raised its target price from HK$43.2 to HK$45.3, maintaining its “buy/high risk” rating and preferred stock status.

Sovleplenib is a highly selective oral SYK inhibitor. It is the company's first hematology product independently developed and commercialized, marking another successful expansion beyond its existing oncology business.

The bank stated that the approval reduces the risk of Hewang Pharmaceutical's immunology/hematology strategy, exposes the company to autoimmune blood diseases, and expands its commercial portfolio other than oncology. The asset has obtained critical positive data for immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (waIHa) to support subsequent life cycle expansion. The bank originally assumed approval in the first half of 2027. Early approval would help commercialize earlier, and initial sales may contribute earlier than previously anticipated. This approval has also allayed investors' concerns about CMC preparations, and global regulatory and production risks have been significantly reduced.

The bank raised Hewang Pharmaceutical's revenue forecast for each year from 2026 to 2028 by 1%, and the net profit forecast was raised by 4%, 2%, and 4%, respectively, as sovleplenib is now included in sales from 2026, and the probability of success (POS) was raised to 100%.